Article

Impact of Community-Based Lymphedema Management on Perceived Disability among Patients with Lymphatic Filariasis in Orissa State, India

Epidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America
PLoS Neglected Tropical Diseases (Impact Factor: 4.45). 03/2013; 7(3):e2100. DOI: 10.1371/journal.pntd.0002100
Source: PubMed

ABSTRACT

Background
Lymphatic filariasis (LF) infects approximately 120 million people worldwide. As many as 40 million have symptoms of LF disease, including lymphedema, elephantiasis, and hydrocele. India constitutes approximately 45% of the world's burden of LF. The Indian NGO Church's Auxiliary for Social Action (CASA) has been conducting a community-based lymphedema management program in Orissa State since 2007 that aims to reduce the morbidity associated with lymphedema and elephantiasis. The objective of this analysis is to evaluate the effects of this program on lymphedema patients' perceived disability.

Methodology/Principal Findings
For this prospective cohort study, 370 patients ≥14 years of age, who reported lymphedema lasting more than three months in one or both legs, were recruited from villages in the Bolagarh sub-district, Khurda District, Orissa, India. The World Health Organization Disability Assessment Schedule II was administered to participants at baseline (July, 2009), and then at regular intervals through 24 months (July, 2011), to assess patients' perceived disability. Disability scores decreased significantly (p<0.0001) from baseline to 24 months. Multivariable analysis using mixed effects modeling found that employment and time in the program were significantly associated with lower disability scores after two years of program involvement. Older age, female gender, the presence of other chronic health conditions, moderate (Stage 3) or advanced (Stage 4–7) lymphedema, reporting an adenolymphangitis (ADL) episode during the previous 30 days, and the presence of inter-digital lesions were associated with higher disability scores. Patients with moderate or advanced lymphedema experienced greater improvements in perceived disability over time. Patients participating in the program for at least 12 months also reported losing 2.5 fewer work days per month (p<0.001) due to their lymphedema, compared to baseline.

Significance
These results indicate that community-based lymphedema management programs can reduce disability and prevent days of work lost. These effects were sustained over a 24 month period.

Download full-text

Full-text

Available from: Katherine E Mues
  • [Show abstract] [Hide abstract]
    ABSTRACT: The range and burden of neglected tropical diseases, many of which are helminth-derived, remains enormous. Infections are rampant in poor districts and although efforts have been implemented over the years, there remains insufficient networks for disease control. In India, experts are encouraging the government to develop a functional public health infrastructure to manage diseases. India has 553 million people at risk for lymphatic filariasis (LF), one of the chronic filarial nematode infections that causes severe morbidity in humans. During coevolution, filariae have developed tactics to modulate the host's immune system so that they can persist for many years. Therefore, most individuals remain asymptomatic and mansonellosis and loiasis are primarily thought of as nuisance infections. Nevertheless, pathology can develop into elephantiasis during LF and Onchocerca volvulus infections can lead to vision loss or skin pathology. Many filarial species require the endosymbiotic Wolbachia bacteria for development and maturation. Indeed, targeting Wolbachia via antibiotic therapy has provided an alternative therapeutic approach which, in contrast to drugs currently employed in mass drug administration programs, is highly macrofilaricidal. This chapter provides an overview about filarial agents drawing upon both their similarities and differences with regards to host immune reactions, ensuing pathologies and how infections alter response to vaccines and other diseases. All of these aspects have to be considered when implementing therapy, especially when adverse side effects may occur. These effects are synopsized in the final section alongside current success stories in terms of elimination and future strategies to control these public health problems.
    No preview · Chapter · Jan 2014
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The Global Program to Eliminate Lymphatic Filariasis aims to interrupt transmission of lymphatic filariasis and manage morbidity in people currently living with the disease. A component of morbidity management is improving health-related quality of life (HRQoL) in patients. Measurement of HRQoL in current management programs is varied because of the lack of a standard HRQoL tool for use in the lymphatic filariasis population. In this study, the psychometric properties of three health status measures were compared when used in a group of lymphatic filariasis patients and healthy controls. The World Health Organization Disability Assessment Schedule 2.0 (WHODAS 2.0), the Dermatology Life Quality Index (DLQI), and the Lymphatic Filariasis Quality of Life Questionnaire (LFSQQ) were administered to 36 stage II and stage III lymphatic filariasis subjects and 36 age and sex matched controls in Kerala, India. All three tools yielded missing value rates lower than 10%, suggesting high feasibility. Highest internal consistency was seen in the LFSQQ (α = 0.97). Discriminant validity analysis demonstrated that HRQoL was significantly lower in the LF group than in controls for the WHODAS 2.0, DLQI, and LFSQQ, but total HRQoL scores did not differ between stage II and stage III lymphedema subjects. The LFSQQ total score correlated most strongly with the WHODAS 2.0 (r = 0.91, p<0.001) and DLQI (r = 0.81, p<0.001). The WHODAS 2.0, DLQI, and LFSQQ demonstrate acceptable feasibility, internal consistency, discriminate validity, and construct validity. Based on our psychometric analyses, the LFSQQ performs the best and is recommended for use in the lymphatic filariasis population.
    Full-text · Article · Feb 2014 · PLoS Neglected Tropical Diseases
  • [Show abstract] [Hide abstract]
    ABSTRACT: The filariasis are a group of diseases caused by nematodes of the Filaroidea family. For their transmission, they require different vectors. Depending on the filarial species, they have a wider distribution, such as Wuchereira bancrofti, or affect a more reduced population group, such as Brugia timori. Dracunculosis (Guinea Worm Disease) is a disease that is being eradicated. The pathogeny of the filariasis is caused by the different interactions between the human immune system with the nematode and its endosymbiotic bacteria Wolbachia. Filariasis can be divided based on the principally affected organ. The group of lymphatic filariasis is made up by: Wuchereria bancrofti, Brugia malayi and Brugia timori. Filariasis with affectation of serous cavities are Mansonella pertans and Mansonella ozzardi. Skin affectation are caused by Mansonella streptocerca, and Dracunculus medinensis. Subcutaneous tissue and conjunctive involvement is characteristic of Loa loa and Onchocerca volvulus. Dirofilariasis is a disease that focally affects the lung parenchyma or subcutaneous tissue. The etiological diagnosis is mainly based on detection and visualization of the microfilarias, in blood or skin. Measures of control of transmission are mainly based on control of vectors and massive pharmacological treatment with the drugs indicated in the different etiologies in endemic countries for some filariasis. Drug treatment is mainly based on the use of diethyl carbamazine, ivermectin and benzimidazoles. In the species in which the present of the endosymbotic bacteria Wolbachia has been demonstrated, doxycycline is also recommended.
    No preview · Article · Apr 2014 · Medicine - Programa de Formación Médica Continuada Acreditado
Show more